TD Cowen Maintains Buy on Revvity, Raises Price Target to $175

10/13/2026
Impact: 70
Healthcare

TD Cowen analyst Dan Brennan has maintained a Buy rating on Revvity (NYSE: RVTY) and increased the price target from $130 to $175.

AI summary, not financial advice

Share: